Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Willis Tower Watson in its divestment of Max Matthiessen
Mandate

Vinge advises Willis Tower Watson in its divestment of Max Matthiessen

May 25, 2020 Banking and Finance EU, Competition and Regulatory M&A Insurance Law Corporate Tax

Vinge advises Willis Tower Watson, global risk adviser, insurance and reinsurance broker, in its divestment of Max Matthiessen to Nordic Capital.

Max Matthiessen was founded 1889 and as active in insurance brokerage and financial advisory services for companies and individuals. The company has 440 employees at approximately 30 locations throughout Sweden with headquarter in Stockholm. In 2019, Max Matthiessen had a customer base of around 13,000 clients with revenues exceeding SEK 1.5 billion. Willis Tower Watson acquired Max Matthiessen from Altor 2014.

The acquisition is conditional upon customary regulatory approvals and conditions to closing.

Vinge’s team consisted of, amongst others, Peter Sundgren, Joacim Rydergård, Stina Bengtsson and Olivia Belding (M&A), Fabian Ekeblad and Paulina Malmberg (Regulatory Insurance), Albert Wållgren (Banking & Finance), Maria Schultzberg (Tax), Xandra Ståhlberg (Competition law) and Nathalie Hughes (VDR-assistant).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025